Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these tre...

Full description

Saved in:
Bibliographic Details
Main Authors: David Simon, Koray Tascilar, Gerhard Krönke, Arnd Kleyer, Mario M. Zaiss, Franz Heppt, Christine Meder, Raja Atreya, Entcho Klenske, Peter Dietrich, Abdullah Abdullah, Thorsten Kliem, Giulia Corte, Harriet Morf, Moritz Leppkes, Andreas E. Kremer, Andreas Ramming, Milena Pachowsky, Florian Schuch, Monika Ronneberger, Stefan Kleinert, Clara Maier, Axel J. Hueber, Karin Manger, Bernhard Manger, Carola Berking, Matthias Tenbusch, Klaus Überla, Michael Sticherling, Markus F. Neurath, Georg Schett
Format: article
Language:EN
Published: Nature Portfolio 2020
Subjects:
Science
Q
Online Access:https://doaj.org/article/e2e3c987d9e84ccb9b7c66bef2e582d6
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.

Similar Items